Small Cap Feast

28th July 2022

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:
No joiners today.
Off The Menu:
No leavers today.

What’s Cooking In The IPO Kitchen?

Inteliqo Limited, intends to join the Aquis Growth Market. Inteliqo Limited provides sales, marketing and distribution services to technology product owners under long-term distribution agreements. The Company has agreed its first such agreement in respect of the Ipedia iQ product range. The iQ product is a smart translation earphone (earbuds) system which offers integrated real time speech translation in 42 languages, built in smart assist (google and siri), multiple built-in microphones and high-definition sound. Expected 5 August.

Unigel Group, intends to join the Aquis Growth Market. Unigel Group is a pioneer in the field of thixotropic gels for the fibre optic cable industry. The Company is also a supplier of laminated steel tapes to the fibre optic cable industry in the US. Thixotropic gels and laminated steel tapes are essential components to the rapidly growing global fibre optic cable market. The Group exports to over 40 countries and is a key supplier to almost every leading fibre optic cable manufacturer worldwide and is the industry’s only organisation with multiple manufacturing facilities spread across 3 continents. The Company acts as the holding company for its wholly-owned operating subsidiary, Unitape Limited and its 60% owned operating subsidiary, Unigel (UK) Limited. Expected 1 August.

Equipmake Holdings intends to join the Aquis Growth Market. Equipmake is a UK-based technology company, which has developed a range of electrification products for the provision of electric vehicle drivetrains to meet the needs of the automotive, aerospace and other sectors in support of the transition from fossil-fuelled to zero emission powertrains. The Company now has a significant pipeline of opportunities of in excess of £400m at various stages of negotiation, as demand for electric vehicles increases as part of the global decarbonisation movement. Expected 29 July.

Georgina Energy, an early-stage resource company with a strategy of actively pursuing the exploration, commercial development and monetisation of helium, hydrogen and hydrocarbon interests located in the Amadeus and Officer Basins in Northern and Western Australia intends to join AIM. Georgina Energy has two principal onshore interests. The first, the Mount Winter Prospect is located in the Amadeus Basin in Northern Australia, which the Company has a right to earn an initial 75% interest. The second interest, the Hussar Prospect is 100% owned by the Company and is located in the Officer Basin in Western Australia. Expected late July.

Macaulay Capital is due to join the Aquis Growth Market on 29 July. The Group was formed to originate and manage corporate transactions, raise funds from third parties, invest the Group’s own funds alongside those of external investors and to manage the Group’s investment portfolio with the aim of maximising its value.

Breakfast Buffet

Altitude Group 26p £18.4m (ALT.L)

The Group has announced results for the year ended 31 March 2022. Revenues increased by 54.9% to £11.9m (2021: £7.7m). Services revenue grew by 17.3%, surpassing the industry average. Adjusted operating profit increased 90.2% to £1.1m (2021: £0.6m). The Group held a cash balance at year end of £0.9m (2021 £2.1m), down from £1.6m at 30 June 2022. AIM membership has continued to grow, and currently totals 2,425 global members, up from 1,917 at acquisition. The Board is confident in the scalability of the business and the management team’s ability to execute upon the Group’s strategy

Cambridge Cognition 135.5p £42.2m (COG.L)

The developer of digital solutions to assess brain health, announces two agreements for post-traumatic stress disorder (PTSD) with a top 10 pharmaceutical company and the United States Department of Defense. The United States Department of Defense is developing a precision medicine approach to PTSD. Cambridge Cognition has been selected as a cognitive assessment provider for the project because CANTABTM offers accurate measurement of the potentially distinct pathophysiological processes involved in PTSD. In the contract with the top 10 pharmaceutical company, Cambridge Cognition will provide CANTABTM as an exploratory endpoint.

Epwin Group 77.5p £112.3m (EPWN.L)

The manufacturer of energy efficient and low maintenance building products, announces its half-year trading update. Revenues were 13% ahead of 2021 comparative period at £178m. Covenant net debt at 30 June 2022 has reduced to £7.3m (31 December 2021: £9.4m) which is 0.3x adjusted EBITDA, providing the Group with in excess of £65m of headroom on its facilities. Raw material costs continued to increase in the first half. Despite the supply chain disruption, the Group has been able to secure sufficient raw materials to meet demand and expects to be able to continue to do so. The Board remains confident of achieving expectations in 2022.

Fintel 202.5p £209.1m (FNTL.L)

A provider of fintech and support services to the UK Retail Financial Services sector today issues a trading update for the six months ended 30 June 2022. Total revenue growth of 2% to £32.2m (HY21: £31.7m). Adjusted EBITDA up 5% to £8.7m (HY21: £8.3m). £7.6m cash and an undrawn £45m Revolving Credit Facility provides financial resources to fund growth both through organic investment and strategic acquisitions.

Fusion Antibodies 49p £12.7m (FAB.L)

The specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the appointment of Dr Adrian Kinkaid as Chief Executive Officer, effective from Monday 15 August 2022. Adrian Kinkaid is a seasoned life sciences executive with 25 years’ experience in life science and biotherapeutics industries. He joins Fusion from Vortex Liquid Biopsy Solutions Ltd and Vortex Biosciences Inc.

Hotel Chocolat 135.5p £186.1m (HOTC.L)

The premium chocolate brand, announces that Hotel Chocolat KK (HCKK), a Japanese joint venture 20% owned by the Group, has obtained Court approval for civil rehabilitation restructuring proceedings (Minji Saisei), pursuant to seeking new sources of capital. The Group had loaned £23m to HCKK in 2018-2022 as working capital. In addition, the Group has entered into guarantee arrangements of up to £5.8m for loans made to HCKK by Japanese leasing companies. The Board has previously acknowledged the potential for a full impairment charge in the FY22 accounts, under IFRS9 relating to revised assessment of probability of recovery on £23m of loans made to HCKK in 2018-2022.

Pod Point 108.8p £166.8m (PODP.L)

The UK-based EV charging solutions provider announces its unaudited half-year results for the period ended 30 June 2022. Revenue grew 57% to £41.6m (H1 2021: £26.5m). Adjusted EBITDA loss of £1.4m (H1 2021: +£0.5m) was a result of reduced gross margin due to higher component costs and the costs of being a listed business. Closing cash was £82.1m. Over 45k charge points installed and shipped in H1 2022 (H1 2021: 27,554), with market share in home charging up by to 22% in H1 2022 (H1 2021: 17%) driven by new deals with car manufacturers and operators of business car fleets.

Sareum Holdings* 197.5p £134.4m (SAR.L)

The specialist drug development company, announces that it has submitted an application for a Clinical Trial Authorisation (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the development of SDC-1801 as a potential new therapeutic for a range of autoimmune diseases with a focus on psoriasis. The company plans to initiate Phase 1 clinical trials in 2022, with a study in psoriasis targeted for 2023. A presentation to investors will take place on 4 August 2022 at 10.00am via the Investor Meet Company platform. Existing and potential investors wishing to participate in the presentation can register here .

Thor Mining 0.5p £9.6m (THR.L)

The gold and tungsten exploration and development company announced the drill results of the diamond drilling program at the 100% owned Molyhil Critical Minerals Project, Northern Territory. Two of the three diamond drill holes completed in late 2021 intercepted disseminated scheelite-molybdenite-chalcopyrite mineralisation hosted in a massive magnetite skarn, validating a newly identified 3D magnetic target. The drilling demonstrates that tungsten-molybdenum-copper skarn mineralisation extends along strike, to the south of the Molyhil Resource. Assay results were lower than visible grade estimates and the samples have been resubmitted for analysis using two different analytical techniques, with further follow up using the coarse reject material.

Virgin Wines 67p £37.4m (VINO.L)

The direct-to-consumer online wine retailers provides a trading update for the year ended 30 June 2022. Total revenue reached £69m (FY21: £73.6m). EBITDA post IFRS was £6.3m (FY21: £7m). Net cash was £7.8m (excluding customers’ WineBank funds) as at 30 June 2022 (FY21: £8.4m). Membership of WineBank (main subscription scheme) increased 8% YOY and revenue from WineBank customers increased 21% YOY. The Group’s focus has been on customer acquisition during the year: 105k new customers acquired across all schemes, 5% ahead of expectations, with cost per recruit below budget and FY21 levels. Q422 customer acquisition are 37% ahead YOY and there is a comprehensive pipeline of new partnership opportunities, giving optimism for the FY23 customer acquisition strategy.

28 July 2022
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram